icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
cn9frEx5Ev82jqHa